Non Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 1st Line

Adenocarcinoma Never-smoking

EGFR Exon 20 Insertions

LUN0112
Phase II Carboplatin + Pemetrexed + Bevacizumab +/- Atezolizumab in Stage IV Non-Squamous NSCLC
PI: Wakelee
NCTN

LUN0113
Phase III TAK-788 First-Line Tx vs Platinum-Based Chemo in NSCLC w/ EGFR Exon 20 Insertion Mutations
PI: Neal
Sponsor: Takeda

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu